Cargando…
Persistent vitreous hemorrhage after intravitreal injection of dexamethasone intravitreal implant in patients with diabetic macular edema
We report three cases of persistent vitreous hemorrhage after injection of a biodegradable 0.7 mg dexamethasone intravitreal implant (Ozurdex, Allergan), (DEX) to treat and manage diabetic macular edema (DME); we also summarize available case reports and review the literature regarding persistent vi...
Autores principales: | Li, Meng-Syuan, Sheu, Shwu-Jiuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947746/ https://www.ncbi.nlm.nih.gov/pubmed/31942436 http://dx.doi.org/10.4103/tjo.tjo_87_17 |
Ejemplares similares
-
Efficacy of intravitreal dexamethasone implant in persistent diabetic macular edema after primary treatment with intravitreal ranibizumab
por: Özata, Kübra, et al.
Publicado: (2019) -
Dexamethasone intravitreal implant in the treatment of diabetic macular edema
por: Dugel, Pravin U, et al.
Publicado: (2015) -
Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema
por: Pacella, Elena, et al.
Publicado: (2013) -
DEXAMETHASONE INTRAVITREAL IMPLANT COMPLICATIONS INCLUDING VITREOUS HEMORRHAGE AND HYPOTONY
por: Yu, Jeffrey J., et al.
Publicado: (2023) -
Letter to the editor: dexamethasone intravitreal implant in the treatment of diabetic macular edema
por: Hall, John
Publicado: (2015)